Aurinia Pharmaceuticals (AUPH) Common Equity (2017 - 2026)

Aurinia Pharmaceuticals' Common Equity history runs 10 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• Quarterly Common Equity rose 210.3% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 210.3% YoY) and the FY2025 annual result came in at $581.3 million, up 54.0% from the prior year.
• Common Equity was $1.1 billion for Q1 2026 at Aurinia Pharmaceuticals, up from $581.3 million in the prior quarter.
• Across five years, Common Equity topped out at $1.1 billion in Q3 2025 and bottomed at $335.3 million in Q2 2025.
• A 5-year average of $483.1 million and a median of $391.9 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity fell 15.37% — and 2026, when it soared 210.3%.
• Aurinia Pharmaceuticals' Common Equity stood at $405.4 million in 2022, then decreased by 6.78% to $378.0 million in 2023, then retreated by 0.13% to $377.5 million in 2024, then surged by 54.0% to $581.3 million in 2025, then soared by 86.92% to $1.1 billion in 2026.
• Business Quant data shows AUPH's Common Equity at $1.1 billion in Q1 2026, $581.3 million in Q4 2025, and $1.1 billion in Q3 2025.